Libo Pharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	801.03	275.42	75.26
Cash & Short-Term Investments	801.03	275.42	75.26
Cash Growth	190.83%	265.95%	-
Other Receivables	1.59	0.54	0.56
Receivables	1.59	0.54	0.56
Inventory	-	1.74	2.02
Prepaid Expenses	124.34	12.74	0.47
Other Current Assets	0.02	-	-
Total Current Assets	926.97	290.44	78.32
Property, Plant & Equipment	2.84	3.71	3.4
Other Intangible Assets	148.43	168.78	13.54
Other Long-Term Assets	4.09	4.93	4.42
Total Assets	1,082	467.87	99.67
Accounts Payable	0	-	-
Accrued Expenses	-	6.19	7.17
Current Portion of Leases	1.32	1.56	1.07
Other Current Liabilities	20.13	0.45	0.35
Total Current Liabilities	21.46	8.21	8.59
Long-Term Leases	-	1.42	2.11
Total Liabilities	21.46	9.62	10.7
Common Stock	752.35	409.23	265.03
Additional Paid-In Capital	614.83	377.63	4.28
Retained Earnings	-296.3	-318.61	-171.33
Comprehensive Income & Other	-10.01	-10.01	-9.01
Shareholders' Equity	1,061	458.24	88.98
Total Liabilities & Equity	1,082	467.87	99.67
Total Debt	1.32	2.98	3.19
Net Cash (Debt)	799.7	272.45	72.08
Net Cash Growth	193.53%	277.99%	-
Net Cash Per Share	12.79	7.27	2.72
Filing Date Shares Outstanding	83.9	40.92	26.5
Total Common Shares Outstanding	83.9	40.92	26.5
Working Capital	905.51	282.24	69.73
Book Value Per Share	12.65	11.20	3.36
Tangible Book Value	912.45	289.47	75.44
Tangible Book Value Per Share	10.88	7.07	2.85
Machinery	-	2.82	9.33
Leasehold Improvements	-	0.48	0.31

Source: S&P Global Market Intelligence. Standard template. Financial Sources.